---
title: "Adjuvant Ovarian Cancer with Cyclin E1 Protein+ ZN-c3-020 GOG-3147 | Sutter Health"
description: "A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression"
url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) /
4.  Adjuvant Ovarian Cancer with Cyclin E1 Protein+ ZN-c3-020 GOG-3147

# Adjuvant Ovarian Cancer Cyclin E1 Protein+ ZN-c3-020 GOG-3147

**Status:** Coming Soon

#### Study details

View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546500).

#### Locations

-   San Francisco

#### Clinical trial FAQs

Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs).

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

![John K Chan, M.D.](https://dyn.mktgcdn.com/p/pjEBXftGFCdPi0LQIN6WcSp3QpqbnJX3LiI6Cwd3g4w/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100)

John K Chan, M.D.

Principal investigator

[View profile](https://www.sutterhealth.org/research/investigators/john-k-chan-md-1049681255)

## Sub-Investigator

[Lejla Delic, M.D.](https://www.sutterhealth.org/research/investigators/lejla-delic-md-1049681192)

## Related clinical trials

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

-   Clinical trial
    
    ### [Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advance-ovarian-cancer-framework-01-j5e-mc-jzxb-2066913418)
    
    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Adjuvant Ovarian Cancer NRG-GY036](https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362)
    
    A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Advanced Ovarian Cancer Catalina-2](https://www.sutterhealth.org/research/clinical-trials/advanced-ovarian-cancer-catalina-2-2023017569)
    
    Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Advanced Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG-3115](https://www.sutterhealth.org/research/clinical-trials/advanced-serous-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-gog-3115-2041490051)
    
    A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Neoadjuvant Ovarian Cancer DESTINY-Ovarian01](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496)
    
    A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)
    
    **Status:** Open to Enrollment
    

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Ovarian Cancer with Cyclin E1 Protein+ ZN-c3-020 GOG-3147"}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948#medicalwebpage","name":"Adjuvant Ovarian Cancer Cyclin E1 Protein+ ZN-c3-020 GOG-3147","description":"A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948","inLanguage":"en-US","dateModified":"2026-11-10","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948#breadcrumblist"},"mentions":[{"@type":"Person","name":"John K Chan, M.D.","url":"https://www.sutterhealth.org/research/investigators/john-k-chan-md-1049681255","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948#medicaltrial","name":"Adjuvant Ovarian Cancer Cyclin E1 Protein+ ZN-c3-020 GOG-3147","alternateName":"A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-cyclin-e1-protein-zn-c3-020-gog-3147-2102453948","description":"A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","identifier":"NCT07546500","code":{"@type":"MedicalCode","codeValue":"NCT07546500","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07546500","status":"https://schema.org/NotYetRecruiting","healthCondition":[{"@type":"MedicalCondition","name":"Ovarian Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]}
```
